Protalix BioTherapeutics Inc(PLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:59 PM ET (Korea 9/12 06:59)
Full metrics table
| Index | RUT | P/E | 11.63 | EPS (ttm) | 0.23 | Insider Own | 3.88% | Shs Outstand | 80.6M | Perf Week | 0.76% |
| Market Cap | 0.21B | Forward P/E | 52.8 | EPS next Y | -79.17% | Insider Trans | - | Shs Float | 77.5M | Perf Month | 0.76% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.02 | Inst Own | 19.41% | Short Float | 4.09% | Perf Quarter | 28.78% |
| Income | 0.02B | P/S | 2.64 | EPS this Y | 400% | Inst Trans | -3.39% | Short Ratio | 4.54 | Perf Half Y | -5.38% |
| Sales | 0.08B | P/B | 2.98 | EPS next 5Y | - | ROA | 20.07% | Short Interest | 3.17M | Perf YTD | 46.67% |
| Book/sh | 0.89 | P/C | 5.14 | EPS past 3/5Y | 35.12% 17.78% | ROE | 31.23% | 52W High | -17.24% ($3.19) | Perf Year | 51.72% |
| Cash/sh | 0.51 | P/FCF | 27.73 | Sales past 3/5Y | 3.45% -3.46% | ROIC | 24% | 52W Low | 65% ($1.60) | Perf 3Y | 50.86% |
| Dividend Est. | - | EV/EBITDA | 7.26 | EPS Y/Y TTM | 181.54% | Gross Margin | 69.2% | Volatility(W/M) | 3.15% 4.83% | Perf 5Y | 76% |
| Dividend TTM | - | EV/Sales | 2.24 | Sales Y/Y TTM | 30.14% | Oper. Margin | 28.89% | ATR (14) | 0.1 | Perf 10Y | -57.28% |
| Dividend Ex-Date | - | Quick Ratio | 1.91 | EPS Q/Q | 2190% | Profit Margin | 23.5% | RSI (14) | 59.3 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.94 | Sales Q/Q | 27.07% | SMA20 | 5.33% ($2.51) | Beta | -0.09 | Target Price | $11 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/12 | SMA50 | 8.68% ($2.43) | Rel Volume | 0.92 | Prev Close | $2.73 |
| Employees | 226 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 600% 53.64% | SMA200 | 16.72% ($2.26) | Avg Volume(3M) | 0.70M | Price | $2.64 |
| IPO | 1996/4/9 | Option/Short | Yes/Yes | Trades | 1538 | Volume | 644,640 | Change | -3.3% |
Company
PLX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 An Israel-based commercial-stage biopharmaceutical company that develops and manufactures treatments for rare diseases using its proprietary plant cell-based expression platform, ProCellEx. Founded in 1993 and headquartered in Karmiel, Israel, the company is commercializing Elfabrio, a treatment for Fabry disease, in collaboration with a global partner.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
PLX makes money exceptionally well
28.89% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +400.0% this year.
Tap to view numbers
The stock looks undervalued
Trading at 11.6 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +50.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 19.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
EES 0.00%
IVSS 0.00%
FLQS 0.00%
VTWG 0.00%It ranks #4 in the industry
Based on market cap of $213M.
PLX $213M PER 11.6
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is PLX?
PLX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PLX?
The market cap of PLX is approximately $213M, ranking 4,075 within its sector.
What is the P/E ratio of PLX?
PLX has a P/E ratio of approximately 11.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PLX?
PLX has recorded a 52-week high of $3.19 and a low of $1.60.
